SLP
HealthcareSimulations Plus, Inc.
$19.20
+$1.09 (+6.02%)
Jan 5, 2026
Price History (1Y)
Analysis
Simulations Plus, Inc. is a healthcare company operating in the health information services industry with 212 employees. The company has a market capitalization of $386.81 million and generated revenue of $79.18 million (TTM). Financially, Simulations Plus, Inc. reported negative net income of -$64,718,000 (TTM), indicating significant losses. However, the company's gross margin is 58.4%, suggesting some level of pricing power or operational efficiency. Returns on equity and assets are -42.1% and 2.7%, respectively, highlighting challenges in generating returns from shareholder capital. The balance sheet shows $32.35 million in cash and $616,000 in debt. The company's valuation metrics include a forward P/E ratio of 17.43 and an EV/EBITDA multiple of 27.07. Revenue growth has been negative at -6.5% (YoY), while earnings growth is not reported. The dividend yield is exceptionally high at 176.0%, with no payout ratio reported, suggesting the company may be prioritizing share buybacks or retention over dividend payments.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Simulations Plus, Inc.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
Visit website →Key Statistics
- Market Cap
- $386.81M
- P/E Ratio
- N/A
- 52-Week High
- $37.67
- 52-Week Low
- $12.39
- Avg Volume
- 389.05K
- Beta
- 1.09
- Dividend Yield
- 176.00%
Company Info
- Industry
- Health Information Services
- Exchange
- NMS
- Country
- United States
- Employees
- 212